Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates

被引:18
|
作者
Sutton, Thomas L. [1 ]
Johnson, Nathalie [2 ]
Schlitt, Alexander [3 ]
Gardiner, Stuart K. [4 ]
Garreau, Jennifer R. [2 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Surg, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA
[2] Legacy Canc Inst, Legacy Med Grp Surg Oncol, 1040 NW 22nd Ave,Suite 560, Portland, OR 97227 USA
[3] Pacific Northwest, Coll Osteopath Med, 200 Mullins Dr, Lebanon, OR 97355 USA
[4] Legacy Hlth, Legacy Res Inst, Devers Eye Inst, 1225 NE 2nd Ave, Portland, OR 97232 USA
关键词
Complications; Breast cancer; Time to surgery; Neoadjuvant chemotherapy; ANTINEOPLASTIC AGENTS; IMPACT; CYCLOPHOSPHAMIDE; SURGERY; DOXORUBICIN; ADRIAMYCIN; MASTECTOMY; DOCETAXEL; OUTCOMES; TIME;
D O I
10.1016/j.amjsurg.2020.02.061
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Neoadjuvant chemotherapy (NAC) is increasingly used in the treatment of breast cancer. The time interval from last dose of cytotoxic chemotherapy to surgery (TTS) can vary widely. We aimed to evaluate the effect of TTS on postoperative complications. Methods: A retrospective review for women treated with NAC at our institution between January 2011 through December 2016 was performed. Charts were reviewed for postoperative wound complications, and multivariate analysis was performed. Results: 455 patients were identified. Median TTS was 30 days (range 11-228). On multivariate analysis, TTS of less than 28 days was associated with 70% higher odds of any wound complication (p < 0.05). Increasing age had the strongest association with the presence of any wound complication (p < 0.0001). The majority of complications were treated in the outpatient setting (n = 80, 83%). Conclusion: Following NAC for breast cancer, TTS less than 28 days is a risk factor for postoperative wound complications; however, the majority of complications are minor and treated in the outpatient setting. Additional data are needed to determine optimal TTS for oncologic outcomes. (C) 2020 Published by Elsevier Inc.
引用
收藏
页码:741 / 745
页数:5
相关论文
共 50 条
  • [1] Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
    Melchior, Nicole M.
    Sachs, Darren B.
    Gauvin, Gabrielle
    Chang, Cecilia
    Wang, Chihsiung E.
    Sigurdson, Elin R.
    Daly, John M.
    Aggon, Allison A.
    Hayes, Shelly B.
    Obeid, Elias I.
    Bleicher, Richard J.
    CANCER MEDICINE, 2020, 9 (08): : 2742 - 2751
  • [2] Thirty-day postoperative morbidity in patients with breast cancer following neoadjuvant chemotherapy
    Srour, Marissa K.
    Lee, Minna
    Walcott-Sapp, Sarah
    Kim, Sungjin
    Amersi, Farin
    Giuliano, Armando E.
    Chung, Alice
    AMERICAN JOURNAL OF SURGERY, 2020, 220 (03) : 660 - 664
  • [3] Influence of surgical timing post-neoadjuvant chemotherapy on survival outcomes in breast cancer patients: A comprehensive systematic review and meta-analysis
    Wang, Dandan
    Sun, Xiaowei
    Sun, Wen
    Wang, Ruoxi
    Pan, Hong
    Zhou, Wenbin
    BREAST, 2025, 81
  • [4] Optimal timing of surgery following breast cancer neoadjuvant chemotherapy: A systematic review and meta-analysis
    Cullinane, Carolyn
    Shrestha, Amber
    Al Maksoud, Ahmed
    Rothwell, Jane
    Evoy, Denis
    Geraghty, James
    McCartan, Damian
    McDermott, Enda W.
    Prichard, Ruth S.
    EJSO, 2021, 47 (07): : 1507 - 1513
  • [5] Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?
    Hatzipanagiotou, Maria Eleni
    Pigerl, Miriam
    Gerken, Michael
    Raepple, Sophie
    Zeltner, Verena
    Hetterich, Madeleine
    Ugocsai, Peter
    Fernandez-Pacheco, Miriam
    Inwald, Elisabeth Christine
    Klinkhammer-Schalke, Monika
    Ortmann, Olaf
    Seitz, Stephan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (13) : 11941 - 11950
  • [6] Impact of time to initiation of postoperative radiotherapy after neoadjuvant chemotherapy on the prognosis of breast cancer: A retrospective cohort study in China
    Xie, Yuxin
    Zhang, Yingjie
    Xie, Keqi
    Zhong, Xiaorong
    Zheng, Hong
    Gou, Qiheng
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (05) : 730 - 738
  • [7] Locoregional Management of Breast Cancer Following Neoadjuvant Chemotherapy
    Marumoto, Ashley D.
    Giuliano, Armando E.
    CURRENT BREAST CANCER REPORTS, 2022, 14 (04) : 103 - 112
  • [8] Short-Term Outcomes Following Breast Cancer Surgery With and Without Neoadjuvant Chemotherapy: A Nationwide Administrative Database Study in Japan
    Konishi, Takaaki
    Fujiogi, Michimasa
    Sato, Ayaka
    Michihata, Nobuaki
    Kumazawa, Ryosuke
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (05) : 3000 - 3010
  • [9] Neoadjuvant chemotherapy in patients with stages II and III breast cancer
    Yuan Zhu
    Qu Xiang
    Zhang Zhong-tao
    Wang Yu
    CHINESE MEDICAL JOURNAL, 2009, 122 (24) : 2993 - 2997
  • [10] Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis
    Luengo-Gil, Gines
    Gonzalez-Billalabeitia, Enrique
    Chaves-Benito, Asuncion
    Garcia Martinez, Elena
    Garcia Garre, Elisa
    Vicente, Vicente
    Ayala de la Pena, Francisco
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (03) : 577 - 587